SOPH: Q3 revenue grew 25% as analysis volumes rose 19%, with adjusted EBITDA loss narrowing

What happened

Sophia Genetics reported that third-quarter revenue grew 25% year over year, while analysis volume increased 19% to a record 118,000. Its adjusted EBITDA loss, a measure of operating results that excludes some items, narrowed to $6.071 million. U.S. and Liquid Biopsy activity supported growth.

Confirmed

Global impact / market context

Revenue growth alongside higher analysis volumes suggests greater use of the company’s services contributed to sales. The narrower adjusted EBITDA loss indicates the gap between revenue and adjusted operating costs became smaller, but the company still reported a loss on this measure.

Analyst inference

The supplied information gives quarterly growth rates and a record volume, but no comparisons with forecasts, cash available, or future guidance. Investors therefore cannot tell from this update alone whether growth is financially sustainable or how quickly the adjusted loss may close.

Analyst inference

What to watch

1. Look for the next reported revenue and analysis-volume figures to see whether service use continues to grow and whether that growth translates into higher sales. Analyst inference
2. Check for further figures on adjusted EBITDA loss, which measures operating results after selected adjustments, to assess whether the reported narrowing continues. Analyst inference
3. Watch for disclosed detail on U.S. and Liquid Biopsy activity, the areas cited as supporting growth, to see whether they remain important contributors. Analyst inference

Evidence

• Original source link unavailable